Its time for genetic testing of clopidogrel response to move into the mainstream, suggests a new scientific statement from the American Heart Association (AHA) that outlines the supporting evidence but also acknowledges the obstacles that still stand in the way of wider adoption.
Clopidogrel, the mainstay oral P2Y12 inhibitor, is a prodrug thats metabolized by the enzyme CYP2C19 before becoming biologically active. But a substantial part of the populationthe prevalence varies by race/ethnicityhas a loss-of-function variation in the CYP2C19 gene. For decades, its been known that patients with this allele have more platelet aggregation and ischemic events than noncarriers while on clopidogrel therapy.
Still, US and European guidelines addressing antiplatelet therapy in CAD havent gone so far as to recommend routine genetic testing, though a few of these documents did give a nod to selective use in situations like dual antiplatelet therapy (DAPT) de-escalation after PCI for ACS.
Writing group chair Naveen L. Pereira, MD (Mayo Clinic, Rochester, MN), told TCTMD that one driver of their new AHA statement is the fact that the guidelines havent yet addressed the latest published clinical trials (POPular Genetics, TAILOR-PCI, PHARMCLO, and IAC-PCI), observational studies, and meta-analyses.
We felt that incorporating data from these studies and providing some guidance to clinicians by interpreting the data, which can be pretty complicated sometimes, would be helpful, said Pereira, who served as a co-principal investigator for the TAILOR-PCI trial.
Beyond this, the authors also collected information on the pharmacology and pharmacokinetics of P2Y12 inhibitors, both genetic and nongenetic determinants of patients response to the drugs, as well as practicalities like reimbursement and how to choose among assays.
Our conclusion was that the evidence to date supports genetic testing, Pereira noted. But in an AHA statement, we cannot directly say, You should do genetic testing. That's up to the guidelines.
As the document points out, many clinicians have positive perceptions about pharmacogenetic testing and its clinical implications, [but fewer than] 10% adopt pharmacogenetic testing in their routine clinical practice, primarily because of a lack of clinical guidelines and pharmacogenetic education.
Indeed, only a very small fraction of practices preemptively genotype, said Pereira. For patients who go on clopidogrel only to fare poorly and experience an event, genetic testing is moot by that point, he explained, since the answer would be to simply give an alternative antiplatelet drug.
Why Clopidogrel Shouldnt Be Skipped
Increasingly, the oral P2Y12 inhibitor of choice isnt clopidogrel but ticagrelor or prasugrelneither of which are dependent on CYP2C19. Some clinicians wonder, why not just avoid the problem of clopidogrel response entirely?
There are physicians who say, I know that having a loss-of-function genotype is a problem when I give clopidogrel, but if I give ticagrelor or prasugrel to all my patients, I don't have to worry about genetic testing, Pereira commented. The problem with this blanket approach is that these drugs are more potent antiplatelets, so on the whole there will be an increase in bleeding incidence. If you want to balance the ischemic and bleeding event risk, it appears that genetic-guided therapy [from the outset] would be an optimal strategy, he added.
Pereira pointed out that multiple studies have shown the cost-effectiveness of using genetic testing to guide antiplatelet therapy. Both clopidogrel and prasugrel are now generic, but not ticagrelor (Brilinta; AstraZeneca), which is considerably more expensive. Medicare considers genetic testing for CYP2C19 loss-of-function alleles to be medically necessary in certain situations, such as when an ACS patient is undergoing PCI, and thus covers its cost. Some commercial payers also offer reimbursement for the testing.
With the availability of point-of-care assays, the logistical hurdles to widespread adoption are also less high. Previously, it could take 2 or 3 days to get results after sending a blood sample for analysis, he noted, but now the testing can be done at bedside with a buccal swab, producing results within an hour.
Naturally, the field loves to see data, Pereira said. While it would be ideal to have a clinical trial comparing genetic-guided therapy versus no testing, with that design, there would be a lot of overlap, since perhaps 70% of patients in the testing arm and 100% of those in the control arm would be taking clopidogrelwith any difference driven by the 30% in the testing arm on another P2Y12 inhibitor. You're going to need tens of thousands of patients to show a difference, so I think doing a trial like that is very difficult at this point, he said. Its easier to see the impact of testing when, as he pointed out was done in a prespecified analysis of TAILOR-PCI, only patients found to have a loss-of-function variant are compared: those given clopidogrel versus those given ticagrelor or prasugrel.
In an AHA statement, we cannot directly say, You should do genetic testing. That's up to the guidelines. Naveen L. Pereira
Overall, Pereira urged, I think it's important to pay attention to evidence in a holistic way. . . . All the data, even though there's not that one big trial showing a difference, really points to [the need] to be careful giving loss-of-function patients clopidogrel. This is especially true when talking about the monotherapy thats happening with newer stents after DAPT de-escalation.
What hed like to see next, said Pereira, is for guidelines to give specific advice on how to use CYP2C19 testing. Clinicians in the meantime should consider looking at [point-of-care] platforms and see how they can incorporate that in their practices so it becomes easy and intuitive. Implementation, the statement adds, depends on the ease not only of performing the tests but also of interpreting their results, as well as knowledge about how to adjust therapy accordingly and the ability to integrate each patients genetic status into the electronic health record for care teams to access.
But What About Platelet Function?
In a commentary published on the AHAs Professional Heart Daily website, Mark B. Effron, MD (John Ochsner Heart and Vascular Institute, New Orleans, LA), highlights the fact that platelet function testing (PFT) is another option for predicting who will benefit from a more-potent antiplatelet agent versus clopidogrel, or from de-escalation of therapy.
In most institutions in the United States, it is easier to obtain results of a platelet aggregation test using VerifyNow than it is to obtain genomics on the patient, he writes. Until . . . there are studies evaluating the benefit of an all-comers genomic strategy versus a directed PFT, there will still be controversy as to which is more appropriate in the management of patients receiving P2Y12 inhibitor therapy.
In their statement, Pereira and colleagues point out that platelet function testing and genetic testing each has advantages and disadvantages.
The key advantage of PFT lies in directly defining the intermediate phenotype of interest (ie, levels of on-treatment platelet reactivity) for which studies have shown an association with clinical outcomes (ie, increased thrombotic and bleeding risks with high and low platelet reactivity, respectively), they say. Nevertheless, its clinical implementation has been challenging given the need for multiple repeated assessments due to potential of variability of results over time and the need for a patient to be on treatment for a certain length of time with a given antiplatelet agent (eg, for at least 12 weeks with clopidogrel) to be able to assess antiplatelet effects and define responsiveness adequately.
Effron agrees that a tailored approach is the way forward, though the exact strategy is still being debated. Whether directed P2Y12 therapy is accomplished through genotype-guided antiplatelet therapy or through PFT, he says, it is becoming clear that patient profiling is needed to determine the best therapy for the patient.
See the original post:
Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA - TCTMD
- Texas A&M Researchers Uncover Secrets Of Horse Genetics For Conservation, Breeding - Texas A&M University Today - November 20th, 2024 [November 20th, 2024]
- Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire - November 20th, 2024 [November 20th, 2024]
- Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance - November 20th, 2024 [November 20th, 2024]
- Precision mutational scanning: your multipass to the future of genetics - Nature.com - November 20th, 2024 [November 20th, 2024]
- Advancements of Haploid Technology in Crops: New Horizons in Breeding and Genetics - Frontiers - November 20th, 2024 [November 20th, 2024]
- Toward advances in retinoblastoma genetics in Kenya - Nature.com - November 12th, 2024 [November 12th, 2024]
- CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production - Nature.com - November 12th, 2024 [November 12th, 2024]
- Genetics Play Key Role in Animal Health and Welfare, Aggression and Handling - Farms.com - November 12th, 2024 [November 12th, 2024]
- Episode 174: Rudy Tanzi talks about genetics, aging and the hallmarks of Alzheimers - IHMC - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Pharmaceutical Technology - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - WV News - October 26th, 2024 [October 26th, 2024]
- Faculty of Science | Protecting Canadas number one crop through genetics - UM Today - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance - October 26th, 2024 [October 26th, 2024]
- Opinion | Fascinated by genetics? Where are the peas Trump made to fornicate? - The Washington Post - October 13th, 2024 [October 13th, 2024]
- Dietary restriction can extend lifespan but genetics matters more - Nature.com - October 13th, 2024 [October 13th, 2024]
- 'They have much stronger players' - Bangladesh assistant coach bizarrely blames 'genetics' for lack of six hitters in the team - Sporting News - October 13th, 2024 [October 13th, 2024]
- Medical Moment: Genetics and breast cancer with USA Health Genetic Counselor Cassie Gurganus - AOL - October 13th, 2024 [October 13th, 2024]
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer - Yahoo Finance - October 13th, 2024 [October 13th, 2024]
- An ideologically-based and misleading critique of how modern genetics is taught - Why Evolution Is True - October 13th, 2024 [October 13th, 2024]
- 2024 Mercedes-AMG C63 Review: Bold But Beholden to Its Genetics - Newsweek - October 2nd, 2024 [October 2nd, 2024]
- Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date - GlobeNewswire - October 2nd, 2024 [October 2nd, 2024]
- Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care... - October 2nd, 2024 [October 2nd, 2024]
- The role of genetics in depression | Second Opinion - KCRW - September 23rd, 2024 [September 23rd, 2024]
- Tilapia genetics company Spring Genetics teams up with UK data firm to improve fish welfare - SeafoodSource - September 23rd, 2024 [September 23rd, 2024]
- Picky eating in kids is mostly due to genetics, study says - Motherly Inc. - September 23rd, 2024 [September 23rd, 2024]
- Research Shows That Fussy Eating In Children Is Mainly Influenced By Genetics - RTTNews - September 23rd, 2024 [September 23rd, 2024]
- Genetics colloquium: Chris Hittinger on the genomic making of metabolic niche breadth Sep. 11 - University of WisconsinMadison - September 15th, 2024 [September 15th, 2024]
- NIH Recognizes Yales Expertise in the Genetics of Rare Diseases - Yale School of Medicine - September 15th, 2024 [September 15th, 2024]
- SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing - PR Newswire - September 15th, 2024 [September 15th, 2024]
- Medicines race dilemma: What science says about genetics and health [PODCAST] - Kevin MD - September 15th, 2024 [September 15th, 2024]
- Researchers want to unlock genetics of the worlds tiniest animals - Popular Science - September 15th, 2024 [September 15th, 2024]
- Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout - Medical Device Network - September 15th, 2024 [September 15th, 2024]
- From farm to future: Technology in genetics - National Hog Farmer - September 2nd, 2024 [September 2nd, 2024]
- Editorial: Plant biotechnology and genetics for sustainable agriculture and global food security - Frontiers - September 2nd, 2024 [September 2nd, 2024]
- NSF Grant Brings Genetics Opportunities to Students in Alabama - Government Technology - September 2nd, 2024 [September 2nd, 2024]
- SBUs Ben Luft brings Lyme expertise to seminal paper on bacterial genetics and evolution - TBR News Media - September 2nd, 2024 [September 2nd, 2024]
- SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference - PR Newswire - September 2nd, 2024 [September 2nd, 2024]
- Singapores National Precision Medicine (NPM) Programme Engages Oxford Nanopore to Advance Understanding of the Genetics of Singapores Multi-Ethnic... - August 5th, 2024 [August 5th, 2024]
- Fulgent Genetics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - August 5th, 2024 [August 5th, 2024]
- Stopped clinical trials give evidence for the value of genetics - Nature.com - August 5th, 2024 [August 5th, 2024]
- What is DSD? Sex genetics and Olympic boxing controversy - Washington Examiner - August 5th, 2024 [August 5th, 2024]
- Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue - The Motley Fool - August 5th, 2024 [August 5th, 2024]
- Viewpoint: Challenging yet another scientifically silly article claiming Black domination of sprinting and long distance running has nothing to do... - August 5th, 2024 [August 5th, 2024]
- Texas Company Trying To Resurrect Woolly Mammoths To Improve Genetics Of Bison - Cowboy State Daily - August 5th, 2024 [August 5th, 2024]
- Genetics confirms Berbers reached North Africa over 20,000 years ago; Arabs came in 7th Century CE - Down To Earth Magazine - August 5th, 2024 [August 5th, 2024]
- Unlocking plant genetics with telomere-to-telomere genome assemblies - Nature.com - July 26th, 2024 [July 26th, 2024]
- Carlo Ancelotti claims Jude Bellingham's 'genetics' are main reason behind Real Madrid & England superstar's meteoric rise to the top - Goal.com - July 26th, 2024 [July 26th, 2024]
- Genetics-based modeling estimates Idaho's wolf population was 1,150 in summer 2023 - Idaho Fish and Game - July 26th, 2024 [July 26th, 2024]
- Lung Cancer Research Foundation Joins Lung Cancer Advocacy Organizations and 23andMe to Launch Lung Cancer Genetics Study to Advance Research - PR... - July 26th, 2024 [July 26th, 2024]
- Fulgent Genetics (FLGT) Scheduled to Post Earnings on Friday - Defense World - July 26th, 2024 [July 26th, 2024]
- SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix - Financial Times - July 26th, 2024 [July 26th, 2024]
- LG Household & Health Care publishes research into the genetics of skin tone - GlobalCosmeticsNews - July 26th, 2024 [July 26th, 2024]
- Estonians gave their DNA to science now they're learning their genetic secrets - Nature.com - June 27th, 2024 [June 27th, 2024]
- Genetic clues to depression revealed in large study - PsyPost - June 27th, 2024 [June 27th, 2024]
- Move Over, Genghis Khan. Many Other Men Left Huge Genetic Legacies - Smithsonian Magazine - June 27th, 2024 [June 27th, 2024]
- 3X4 Genetics Selected as Partner for Preeminent Cancer Research and Treatment Nonprofit, The Metabolic Terrain ... - BioSpace - June 27th, 2024 [June 27th, 2024]
- NIFA Invests $6M in Animal Breeding, Genetics and Genomics | NIFA - National Institute of Food and Agriculture - June 27th, 2024 [June 27th, 2024]
- Arbel Harpak: Pursuing the Next Frontier in Genetics | Dell Medical School - Dell Medical School - June 27th, 2024 [June 27th, 2024]
- Coffee habits are partly linked to genetics, UC San Diego researchers say - NBC San Diego - June 27th, 2024 [June 27th, 2024]
- Advanced genetic tools help researchers ID new neurodevelopmental syndrome - Yale News - June 27th, 2024 [June 27th, 2024]
- Nutritious diet may protect against type 2 diabetes, regardless of genetics - News-Medical.Net - June 27th, 2024 [June 27th, 2024]
- Genome-wide association study identifies host genetic variants influencing oral microbiota diversity and metabolic ... - Nature.com - June 27th, 2024 [June 27th, 2024]
- Unlock the Secrets of Your DNA with Advanced Genetic Testing - North Forty News - June 27th, 2024 [June 27th, 2024]
- Modern and precise: Using gene editing to change the blueprint of an organism - Beef Magazine - June 27th, 2024 [June 27th, 2024]
- The 'gene deserts' unravelling the mysteries of disease - BBC.com - June 27th, 2024 [June 27th, 2024]
- UGA plant geneticists are tackling the climate crisis - Longview News-Journal - June 27th, 2024 [June 27th, 2024]
- Bringing Gene Therapy to the Brain - The Scientist - June 27th, 2024 [June 27th, 2024]
- The importance of the paradise fish in evolutionary and behavioral genetics research - Phys.org - June 9th, 2024 [June 9th, 2024]
- What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing? - Yahoo Finance - June 9th, 2024 [June 9th, 2024]
- UW initiative aims to bring together social sciences and genetics - Wisbusiness.com - June 9th, 2024 [June 9th, 2024]
- Women have a higher genetic risk for PTSD, according to study by VCU and Swedish researchers - VCU News - June 9th, 2024 [June 9th, 2024]
- Genetics study points to potential treatments for restless leg syndrome - University of Cambridge news - June 9th, 2024 [June 9th, 2024]
- deCODE genetics: The rate, nature and transmission of mitochondrial DNA mutations in humans - PR Newswire - June 9th, 2024 [June 9th, 2024]
- Genetic association mapping leveraging Gaussian processes | Journal of Human Genetics - Nature.com - June 9th, 2024 [June 9th, 2024]
- Minimally destructive hDNA extraction method for retrospective genetics of pinned historical Lepidoptera specimens ... - Nature.com - June 9th, 2024 [June 9th, 2024]
- Restless legs syndrome tied to 140 'hotspots' in the genome - Livescience.com - June 9th, 2024 [June 9th, 2024]
- Paired tumor-germline testing can enhance patient carewith guidance from genetics specialists - The Cancer Letter - June 9th, 2024 [June 9th, 2024]
- Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets - Nature.com - June 9th, 2024 [June 9th, 2024]
- Genetic Risk Score Revolutionizes TNBC Prediction in Black Women - Targeted Oncology - June 9th, 2024 [June 9th, 2024]